Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 12 (2025)
International Multidisciplinary Journal for Research & Development

Articles

LIVER FIBROSIS AND DISORDERS OF LIPID METABOLISM IN NON‑ALCOHOLIC FATTY LIVER DISEASE

Published 2025-12-22

  • Raisa Sharobiddinovna Sayfutdinova
    • ,
  • Zarnigor Azamatovna Nazirova

Raisa Sharobiddinovna Sayfutdinova
PhD (Medicine), Associate Professor, Department of Endocrinology, Andijan State Medical Institute

Zarnigor Azamatovna Nazirova
Assistant, Department of Endocrinology, Andijan State Medical Institute

Abstract

Objective. To evaluate the relationship between liver fibrosis stage and lipid metabolism parameters in patients with non‑alcoholic fatty liver disease (NAFLD).

 

Keywords

non‑alcoholic fatty liver disease, liver fibrosis, lipid metabolism, triglycerides, atherogenic index.

PDF

References

  1. Antyukh KY, Grigorenko EA, Mitkovskaya NP. The impact of liver fibrosis on lipid metabolism in patients with arterial hypertension and NAFLD. Cardiology Bulletin. 2024.
  2. Clinical Guidelines of the Russian Federation. Non‑alcoholic fatty liver disease in adults. Ministry of Health of the Russian Federation, Scientific Society of Gastroenterologists of Russia. 2022.
  3. Drapkina OM, Shepel RN, Yakovenko EP, Zyatenkova EV. Non‑invasive methods for detecting progressive fibrosis in patients with NAFLD. Preventive Medicine. 2019;22(2):182–190. doi:10.17116/profmed20192202182.
  4. Ivashkin VT, Maev IV, Trukhmanov AS, et al. Non‑alcoholic fatty liver disease: clinical guidelines. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24–60.
  5. Maev IV, Andreev DN, Kucheryavy YuA. Modern approaches to the diagnosis and treatment of NAFLD. Therapeutic Archive. 2018;90(5):4–12.
  6. Ivashkin VT, Pavlov ChS, Maev IV, et al. Algorithms for the diagnosis and treatment of NAFLD. Clinical Medicine. 2020;98(7):512–520.
  7. Grigorieva IN, Sorokina EV. Metabolic syndrome and NAFLD: relationship with lipid metabolism. Bulletin of the Russian Academy of Medical Sciences. 2019;74(3):210–216.
  8. Shepel RN, Drapkina OM. The role of the lipid profile in the progression of liver fibrosis in NAFLD. Cardiology. 2021;61(10):45–52.
  9. Kuchkarov ShT, Ergashev KhM. Respiratory support and metabolic disorders in NAFLD. Economics and Society. 2023;5(102):23–27.
  10. Ministry of Health of Uzbekistan. Medical protocol: Non‑alcoholic fatty liver disease in adults. MedElement. 2024.
  11. Tilg H., Adolph T.E., Dudek M., Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3:123–135. doi:10.1038/s42255-021-00501-9.
  12. Yang B., Gong M., Zhu X., et al. Correlation between liver fibrosis in NAFLD and insulin resistance indicators: NHANES 2017–2020. Front Endocrinol. 2025;16:1514093. doi:10.3389/fendo.2025.1514093.
  13. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of NAFLD: Practice guidance. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367.
  14. Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of NAFLD. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431.
  15. Byrne C.D., Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62(1):S47–S64. doi:10.1016/j.jhep.2014.12.012.
  16. Eslam M., Sanyal A.J., George J. MAFLD: A consensus-driven definition. Lancet Gastroenterol Hepatol. 2020;5(4):273–286. doi:10.1016/S2468-1253(19)30318-2.
  17. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: Natural history of NAFLD and diagnostic accuracy of non-invasive tests. Ann Med. 2011;43(8):617–649. doi:10.3109/07853890.2010.518623.
  18. Adams L.A., Anstee Q.M., Tilg H., Eslam M. NAFLD and liver fibrosis: biomarkers and risk prediction. Nat Rev Gastroenterol Hepatol. 2020;17(9):546–559. doi:10.1038/s41575-020-0316-3.
  19. Wong V.W., Adams L.A., de Lédinghen V., et al. Noninvasive biomarkers in NAFLD and NASH. Nat Rev Gastroenterol Hepatol. 2018;15(8):461–478. doi:10.1038/s41575-018-0014-9.
  20. Targher G., Byrne C.D., Tilg H. NAFLD and increased cardiovascular risk: clinical associations. Nat Rev Gastroenterol Hepatol. 2021;18(9):623–632. doi:10.1038/s41575-021-00474-3.

Downloads

Download data is not yet available.